A realistic timeline, based on where the Phase 3 programme is now, looks like this: FDA submission in the U.S.: late 2026 or 2027 FDA approval: 2027 or 2028 UK MHRA review: typically 12 to 24 months after FDA approval NHS access through a NICE appraisal: a separate process, usually 12 to 24 months after MHRA approval The earliest UK private access through online pharmacies, mirroring how Mounjaro and Wegovy first launched here, is likely 2027 or 2028
Tubular injury causing protracted glycosuria following withdrawal of a sodium-glucose cotransporter 2 (SGLT2) inhibitor: A possible role in the development of protracted hypoglycemia and ketoacidosis
With high absorption, it soothes rough patches caused by dryness and helps maintain long-lasting hydration for improved skin condition
Furthermore, many patients taking Ozempic for type 2 diabetes are also prescribed metformin, creating a dual risk for B12 deficiency
Assuming they're getting enough because they feel fine: Muscle loss happens gradually